Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Connie N Hess

Showing results (61-70 of 85) with videos related to

Pageof 9
Sort By:
Journal of the American College of Cardiology|May 19, 2021
Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD TrialRupert M Bauersachs, Michael Szarek, Marianne Brodmann, et al.
Journal of the American College of Cardiology|August 14, 2015
Apixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights From the APPRAISE-2 TrialConnie N Hess, Stefan James, Renato D Lopes, et al.
Circulation. Cardiovascular Interventions|February 27, 2026
Low-Dose Rivaroxaban Plus Aspirin in Patients With PAD Undergoing Lower Extremity Revascularization With and Without History of Prior Limb Revascularization: Insight From the VOYAGER-PAD TrialMario Enrico Canonico, Jessica Parr, E Sebastian Debus, et al.
American Heart Journal|July 29, 2014
Independent data monitoring committees: preparing a path for the futureConnie N Hess, Matthew T Roe, C Michael Gibson, et al.
European Heart Journal|August 23, 2023
Women, lipids, and atherosclerotic cardiovascular disease: a call to action from the European Atherosclerosis SocietyJeanine E Roeters van Lennep, Lale S Tokgözoğlu, Lina Badimon, et al.
Journal of Thrombosis and Haemostasis : JTH|February 16, 2022
Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy aloneScott D Berkowitz, Rupert M Bauersachs, Michael Szarek, et al.
American Heart Journal|April 30, 2017
Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndromeConnie N Hess, Robert M Clare, Megan L Neely, et al.
Circulation|November 3, 2020
Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and SafetyWilliam R Hiatt, Marc P Bonaca, Manesh R Patel, et al.
JAMA Network Open|June 22, 2022
Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity RevascularizationConnie N Hess, Michael Szarek, Sonia S Anand, et al.
European Heart Journal|August 25, 2021
Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trialMori J Krantz, Sebastian E Debus, Judith Hsia, et al.
Pageof 9

Showing results (61-70 of 85) with videos related to

Sort By:
Pageof 9
Journal of the American College of Cardiology|May 19, 2021
Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD TrialRupert M Bauersachs, Michael Szarek, Marianne Brodmann, et al.
Journal of the American College of Cardiology|August 14, 2015
Apixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights From the APPRAISE-2 TrialConnie N Hess, Stefan James, Renato D Lopes, et al.
Circulation. Cardiovascular Interventions|February 27, 2026
Low-Dose Rivaroxaban Plus Aspirin in Patients With PAD Undergoing Lower Extremity Revascularization With and Without History of Prior Limb Revascularization: Insight From the VOYAGER-PAD TrialMario Enrico Canonico, Jessica Parr, E Sebastian Debus, et al.
American Heart Journal|July 29, 2014
Independent data monitoring committees: preparing a path for the futureConnie N Hess, Matthew T Roe, C Michael Gibson, et al.
European Heart Journal|August 23, 2023
Women, lipids, and atherosclerotic cardiovascular disease: a call to action from the European Atherosclerosis SocietyJeanine E Roeters van Lennep, Lale S Tokgözoğlu, Lina Badimon, et al.
Journal of Thrombosis and Haemostasis : JTH|February 16, 2022
Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy aloneScott D Berkowitz, Rupert M Bauersachs, Michael Szarek, et al.
American Heart Journal|April 30, 2017
Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndromeConnie N Hess, Robert M Clare, Megan L Neely, et al.
Circulation|November 3, 2020
Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and SafetyWilliam R Hiatt, Marc P Bonaca, Manesh R Patel, et al.
JAMA Network Open|June 22, 2022
Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity RevascularizationConnie N Hess, Michael Szarek, Sonia S Anand, et al.
European Heart Journal|August 25, 2021
Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trialMori J Krantz, Sebastian E Debus, Judith Hsia, et al.
Pageof 9